Scholarlink

<p>Histone deacetylases (HDACs) are epigenetic regulators frequently altered in cancer. Here we report that overexpression of <i>HDAC1</i>/2 occurs in Hepatocellular Carcinoma (HCC) patients, correlating with poor prognosis. We show that romidepsin, a class-I HDAC inhibitor, elicits a combinatorial perturbation of distinct molecular processes in HCC cells, altering lipid composition, mitotic spindle machinery, and levels of cell cycle/survival signals. Collectively, these alterations lead HCC cells to a vulnerable state, conferring dependency to receptor tyrosine kinase (RTK) signalling support. The cytostatic effects of romidepsin alone is converted into cytotoxicity by the RTK inhibitor cabozantinib in HCC models. We document that romidepsin+cabozantibib confers an immune-stimulatory profile in <i>Alb-R26</i><sup><i>Met</i></sup> mouse models, with direct effects on primary human dendritic cell maturation in vitro. Our findings put forward the intricate crosstalk between epigenetics, metabolism, and immune response in cancer. The broad action of romidepsin on distinct cellular functions highlights its therapeutic potential for HCC treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月25日

查看全文
  • Celia Sequera,
  • Margherita Grattarola,
  • Floriane Cannet,
  • Aurélie Dobric,
  • Paula Michea Veloso,
  • Melissa Methia,
  • Sylvie Richelme,
  • Abdessamad El Kaoutari,
  • Paraskevi Kousteridou,
  • Delphine Debayle,
  • Lukas Kübler,
  • Sandro Nuciforo,
  • Yannick Boursier,
  • Mathieu Dupont,
  • Stefania Pizzimenti,
  • Giuseppina Barrera,
  • Jean-William Dupuy,
  • Frédéric Saltel,
  • Markus H. Heim,
  • Sophie Vasseur,
  • Xavier Adhoute,
  • Fabienne Guillaumond,
  • Jean-Paul Borg,
  • Christian Morel,
  • Flavio Maina

摘要

Histone deacetylases (HDACs) are epigenetic regulators frequently altered in cancer. Here we report that overexpression of HDAC1/2 occurs in Hepatocellular Carcinoma (HCC) patients, correlating with poor prognosis. We show that romidepsin, a class-I HDAC inhibitor, elicits a combinatorial perturbation of distinct molecular processes in HCC cells, altering lipid composition, mitotic spindle machinery, and levels of cell cycle/survival signals. Collectively, these alterations lead HCC cells to a vulnerable state, conferring dependency to receptor tyrosine kinase (RTK) signalling support. The cytostatic effects of romidepsin alone is converted into cytotoxicity by the RTK inhibitor cabozantinib in HCC models. We document that romidepsin+cabozantibib confers an immune-stimulatory profile in Alb-R26Met mouse models, with direct effects on primary human dendritic cell maturation in vitro. Our findings put forward the intricate crosstalk between epigenetics, metabolism, and immune response in cancer. The broad action of romidepsin on distinct cellular functions highlights its therapeutic potential for HCC treatment.